Compare FVRR & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | VSTM |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 395.4M |
| IPO Year | 2019 | 2011 |
| Metric | FVRR | VSTM |
|---|---|---|
| Price | $10.50 | $5.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $18.43 | $16.50 |
| AVG Volume (30 Days) | 706.2K | ★ 3.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $282.64 |
| Revenue Next Year | $1.83 | $72.25 |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $9.58 | $3.43 |
| 52 Week High | $28.00 | $11.25 |
| Indicator | FVRR | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 67.17 |
| Support Level | $9.93 | $5.53 |
| Resistance Level | $11.43 | $6.48 |
| Average True Range (ATR) | 0.47 | 0.47 |
| MACD | -0.03 | 0.11 |
| Stochastic Oscillator | 3.89 | 85.31 |
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.